13,254 Shares in Boston Scientific Corporation $BSX Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,254 shares of the medical equipment provider’s stock, valued at approximately $1,294,000.

Several other hedge funds have also recently modified their holdings of the company. Ausdal Financial Partners Inc. bought a new position in shares of Boston Scientific in the third quarter valued at approximately $281,000. Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in Boston Scientific by 194.2% during the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 104,785 shares of the medical equipment provider’s stock worth $10,225,000 after acquiring an additional 69,174 shares during the period. Bridgefront Capital LLC boosted its position in Boston Scientific by 90.1% in the third quarter. Bridgefront Capital LLC now owns 26,318 shares of the medical equipment provider’s stock worth $2,569,000 after purchasing an additional 12,471 shares during the last quarter. Boothbay Fund Management LLC grew its stake in Boston Scientific by 1,079.0% in the 3rd quarter. Boothbay Fund Management LLC now owns 28,250 shares of the medical equipment provider’s stock valued at $2,758,000 after purchasing an additional 25,854 shares during the period. Finally, Anchor Investment Management LLC grew its stake in Boston Scientific by 14.4% in the 3rd quarter. Anchor Investment Management LLC now owns 9,513 shares of the medical equipment provider’s stock valued at $929,000 after purchasing an additional 1,199 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis arguing the stock’s pullback may be overdone given solid fundamentals and recent financial results, which helps explain why investors are buying despite legal headlines. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Negative Sentiment: Multiple securities class actions and investor notices allege Boston Scientific misled investors about growth and competitive risks in its U.S. Electrophysiology segment; law firms are soliciting lead-plaintiff applicants ahead of a May 4, 2026 deadline, increasing potential litigation exposure and headline risk. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Rosen Law Firm reminder: purchasers of BSX between July 23, 2025 and Feb 3, 2026 have until May 4, 2026 to seek lead-plaintiff status in the securities fraud action — more publicity and potential consolidation of claims. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Faruqi & Faruqi issues an investor reminder about the same May 4 deadline and is investigating potential claims tied to disclosures during the Class Period — another firm adding legal resources and publicity. BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors with substantial losses about opportunities to lead a class action, repeating allegations that the company misled investors on its U.S. EP segment — amplifies potential class consolidation and damages exposure. INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
• Negative Sentiment: Several other plaintiff firms (Glancy Prongay Wolke & Rotter; Bronstein Gewirtz & Grossman; additional Rosen/Faruqi notices) have filed or circulated similar investor-alerts — increasing the odds of coordinated litigation activity and legal costs for BSX. ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX

Boston Scientific Trading Up 0.9%

Shares of BSX opened at $69.77 on Tuesday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The business has a 50-day moving average of $81.95 and a 200 day moving average of $92.95. The firm has a market cap of $103.53 billion, a P/E ratio of 35.96, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday. Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Oppenheimer lowered their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $108.00.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.